trending Market Intelligence /marketintelligence/en/news-insights/trending/-VhFat4vQK5H2xDXdHNj6A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

PhaseBio secures $120M funding commitment for lead asset

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

PhaseBio secures $120M funding commitment for lead asset

Malvern, Pa.-based biopharmaceutical company PhaseBio Pharmaceuticals Inc. said it had entered a financing and co-development collaboration with SFJ Pharmaceuticals Inc. to advance its lead asset PB2452.

SFJ Pharmaceuticals is a global drug development company backed by venture capital firms Blackstone Life Sciences and Abingworth.

Under the agreement, SFJ will pay up to $120 million to support the global development of PB2452, which is designed to reverse the antiplatelet activity of AstraZeneca PLC's blood thinner ticagrelor in major bleeding and urgent surgery situations.

SFJ will fund up to $90 million of development expenses through the end of 2021 and up to an additional $30 million based on PhaseBio meeting specific, pre-defined clinical milestones for PB2452. In exchange, SFJ will assume a central role in global clinical development and regulatory activities for PB2452 outside the U.S.

However, PhaseBio is required to make repayments to SFJ over seven to eight years following receipt of regulatory approvals for the medicine in the U.S., the EU, and either China or Japan. The amount to be repaid will be capped at five times the amount funded by SFJ.

PhaseBio will retain exclusive worldwide commercial rights to PB2452 and will not owe any payments from a territory where it is not approved.